AT 132

Drug Profile

AT 132

Alternative Names: AT-001 - Audentes Therapeutics/Genethon; AT-132

Latest Information Update: 16 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Audentes Therapeutics; Genethon
  • Developer Audentes Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference; Myotubularin expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Congenital structural myopathies
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Congenital structural myopathies

Most Recent Events

  • 16 Aug 2018 Updated efficacy data from the phase I/II ASPIRO trial in Congenital structural myopathies (X-linked myotubular myopathy) released by Audentes Therapeutics
  • 05 Jun 2018 AT 132 receives Priority Medicine (PRIME) status for Congenital structural myopathies in European Union
  • 16 May 2018 Interim adverse events and efficacy data from the phase I/II ASPIRO trial in Congenital structural myopathies (X-linked myotubular myopathy) released by Audentes Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top